# A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

Clinical trial · Verve Therapeutics, Inc.

- Archive id: nct:NCT07839936
- Published: 2026-09-24
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07839936
- Source URL: https://clinicaltrials.gov/study/NCT07839936
- Provenance: clinicaltrials

## Abstract

The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: HEART-3
- status: NOT_YET_RECRUITING
- phase: PHASE2
- study type: INTERVENTIONAL
- enrollment: 175
- sponsor: Verve Therapeutics, Inc.
- conditions: Atherosclerosis; Cardiovascular Disease; Hypercholesterolemia
- interventions: DRUG: VERVE-102; DRUG: Placebo
- start date: 2026-10-01
- start date type: ESTIMATED
- primary completion date: 2028-08-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [CRISPR & Gene-Editing Therapies](https://space-kitty.com/topics/gene-editing-therapies)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.